CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Ketorolac Tromethamine 0.45% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01023724
NCT01023724Phase 4Completed

A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID

Bucci Laser Vision Institute·interventional·Posted Dec 2, 2009·Updated Aug 26, 2011

In Brief

A Phase 4 clinical trial evaluating Ketorolac Tromethamine 0.45% and Bromfenac 0.09% for Post Operative Anterior Chamber Inflammation (Flare). Completed, enrolled 50 participants across 1 site.

Detailed Summary

Approximately 50 patients undergoing cataract surgery will be randomized in an even allocation (1:1) into two treatment groups, either ketorolac 0.45% BID or bromfenac 0.09% BID. Patients will be instructed to begin dosing study medication in the operative eye the day before surgery and continue dosing until day 14. KOWA flare measurements will be performed at postoperative day one and postoperative day 14. The amount of anterior chamber inflammation (flare) will be objectively measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsAllergan

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2, 2009
Enrollment StartDec 1, 2009
Primary CompletionJan 1, 2010
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 16.6 years ago

Interventions

Ketorolac Tromethamine 0.45%drug

Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.

Bromfenac 0.09%drug

Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively